The present invention relates to a pyridazinone or pyridazine compound and a derivative and a pharmaceutical composition thereof. Specifically, the present invention provides a pyridazinone or pyridazine compound as shown in formula (I) or (Ia), or a stereoisomer, tautomer, enantiomer, diastereoisomer, resonant body, pharmaceutically acceptable salt, hydrate, solvate, or crystal form thereof. The compound as shown in formula (I) or (Ia) has an excellent agonistic effect and pharmacodynamic property on a thyroid hormone β receptor.

##STR00001##

The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.

##STR00001##

This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Provided is a substituted pyrimidine or pyridine amine derivative represented by formula (I), and a pharmaceutically acceptable salt, solvate, stereoisomer, prodrug, and pharmaceutical composition thereof, as well as medical application thereof. The derivative has significant adenosine A.sub.2A receptor and/or adenosine A.sub.2B receptor antagonistic activities.

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds. ##STR00001##

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I):

##STR00001##

wherein L.sub.1, A, X.sub.1, X.sub.2, R.sup.1, R.sup.2, and R.sup.3 are described herein.

The present disclosure relates to an electrochromic material having a relatively high response speed and a reversible discoloration even by a relatively low driving voltage and an electrochromic particle, a transmittance variable panel and a transmittance variable display device including the electrochromic material.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

An organogold nonlinear optical chromophore includes gold complexed with a fluorophore optionally substituted an organophosphine ligand or an N-heterocyclic carbene ligand.